NECTAR Study: Neoadjuvant Toripalimab + 9MW2821 for Local UTUC

The NECTAR study is a multicenter, open-label, randomized phase II clinical trial designed to evaluate a neoadjuvant treatment strategy in patients with localized upper tract urothelial carcinoma (UTUC). In this study, eligible participants will be randomly assigned to receive either neoadjuvant treatment with toripalimab plus the investigational drug 9MW2821 followed by radical nephroureterectomy with or without lymph node dissection, or upfront radical nephroureterectomy with or without lymph node dissection as standard of care. The purpose of the study is to compare the pathologic response at the time of surgery between the two treatment approaches and to assess treatment safety. Participants will be monitored throughout treatment and follow-up for treatment response, adverse events, and other clinical outcomes. The information obtained from this study may help improve future treatment strategies for patients with localized UTUC.

NCT Number	NCT07412171
Lead Sponsor	Peking University Third Hospital Collaborators: Jiangsu Provincial People's Hospital, Peking University Cancer Hospital & Institute, Beijing Friendship Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Affiliated Hospital of Kunming Medical University
Conditions	Upper Tract Urothelial Carcinoma
Enrollment	40 participants
Start Date	2026-02
Primary Completion	2028-12 (estimated)
Study Completion	2028-12 (estimated)
Updated on ClinicalTrials.gov	2026-02-17